http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20170118960-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ca7d5556b943cb66ff8be8d3239d7911 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-17 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M5-00 |
| filingDate | 2011-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14ad220503edc28ed785a7f37a6b53e1 |
| publicationDate | 2017-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20170118960-A |
| titleOfInvention | Methods of Intravenous Administration of Glyburide and other Drugs |
| abstract | Glyburide, or another drug is disclosed. The novel methods disclosed herein include intravenous methods of administering glyburide, or other drugs, over a period of one hour or more, preferably over a period of about 72 hours. A novel method is the administration of glyburide, or other drug, followed by the first continuous infusion of glyburide, or other drug; And optionally, a second or additional daily administration of glyburide, or other drug, and / or a second or additional continuous infusion of the glyburide, or other drug. These methods are effective in quickly achieving the desired level of glyburide, or other drug, and providing a substantially constant level of glyburide, or other drug, over a desired period of time. The methods disclosed herein can be used for the treatment of acute stroke (ischemic and hemorrhagic), traumatic brain injury (TBI), spinal cord injury (SCI), myocardial infarction (MI), shock (including hemorrhagic shock) Lt; / RTI > may be useful for treating individuals in need of treatment for < RTI ID = 0.0 > These methods provide rapid onset and persistence of therapeutic glyburide, or other drug plasma levels, over an extended period of time, and further avoid excessive levels of drug, thus avoiding drug side effects. |
| priorityDate | 2010-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 157.